Home › Immunocore And Lilly Announce Immunotherapy-Based Clinical Trial Collaboration In Melanoma
 

Keywords :   


Immunocore And Lilly Announce Immunotherapy-Based Clinical Trial Collaboration In Melanoma

2015-07-01 08:13:50| drugdiscoveryonline Home Page

Immunocore Limited and Eli Lilly and Company recently announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore’s lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma

Tags: trial clinical collaboration announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Eastern North Pacific Tropical Weather Outlook
29.09Atlantic Tropical Weather Outlook
29.09Hurricane Isaac Graphics
29.09Hurricane Isaac Forecast Discussion Number 13
29.09Tropical Storm Joyce Graphics
29.09Hurricane Isaac Wind Speed Probabilities Number 13
29.09Hurricane Isaac Public Advisory Number 13
29.09Summary for Hurricane Isaac (AT5/AL102024)
More »